AstraZeneca retires MedImmune brand

The MedImmune name is going away. The Gaithersburg-based research-and-development arm of AstraZeneca PLC (NYSE: AZN) will be folded into its parent as the U.K. company reorganizes its R&D units, the company announced Thursday. The MedImmune brand and logo will disappear, but the Maryland operation will remain as one of AstraZeneca's three R&D sites. Sunsetting the MedImmune brand is “designed to simplify our structure and help make the company more aligned,” a spokeswoman told me in an email.…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news